



# NASH Roundtable™

A Forum for Collaborative Science & Translational Clinical Research

## Leading hepatologists, endocrinologists and clinical development experts addressing challenges in NASH drug development

The NASH Roundtable was established in 2018 to accelerate the advancement and application of scientific methods and strategies for NASH clinical research. Its members are distinguished scientific and clinical development experts brought together by their common commitment to steward advances in science, clinical research and therapeutics for nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH).

The NASH Roundtable meets twice yearly and is a forum to support the development of effective and safe treatments and build consensus towards validated biomarkers and clinical trial endpoints.

Roundtable members represent cross-functional expertise in NASH research, drug development and patient care, and hail from prominent academic and medical centers in North America, Europe and Asia.

Accessible to biopharma to consult on NASH development programs

- Clinical development and regulatory planning
- Clinical and pre-clinical study design
- Biomarker strategies
- Applicable & relevant clinical research methods
- Asset evaluation and risk assessment
- Competitive and scientific landscape review

## Distinguished NASH Roundtable Members

### Elisabetta Bugianesi MD, PhD

Professor of Gastroenterology, School Medicine at the University of Torino, Italy

### Kenneth Cusi, MD

Professor and Chief, Division of Endocrinology, Diabetes and Metabolism at University of Florida

### Scott L. Friedman, MD

Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at Icahn School of Medicine at Mount Sinai

### Marcus Homepesch, MD

Chief Executive Officer and Chairman of the Board, ProSciento, Inc.

### Eric Lawitz, MD

Medical Director and Vice President of Research and Development at the Texas Liver Institute and Clinical Professor of Medicine at the University of Texas Health San Antonio

### Rohit Loomba, MD

Professor of Medicine, Director of Hepatology, at University of California at San Diego and Founding Director of the UCSD NAFLD Research Center

### Vlad Ratziu, MD, PhD

Professor of Hepatology at Sorbonne Université and Pitié-Salpêtrière Hospital

### Mary Rinella, MD

Professor of Medicine at Feinberg School of Medicine, Northwestern University

### Michael Roden, MD

Director of the Deutsches Diabetes Zentrum and the Division of Endocrinology and Diabetology at Düsseldorf University Hospital

### Manuel Romero-Gómez, MD

Professor of Medicine at University of Seville, Director of Digestive, Liver and Inflammatory Diseases Program at Institute of Biomedicine of Seville and UCM Digestive Diseases at Virgen del Rocio University Hospital

### Arun J. Sanyal, MD, FAASLD

Z. Reno Vlahcevic Professor of Medicine at Virginia Commonwealth University School of Medicine

### Detlef Schuppan, MD, PhD

Professor of Medicine, Hepatology and Gastroenterology, at Mainz University Medical Center and Beth Israel Deaconess Medical Center at Harvard Medical School

### Miriam Vos, MD, MSPH

Associate Professor, Pediatrics and Division of Gastroenterology, Hepatology and Nutrition, at Emory University School of Medicine and Director, Pediatric Fatty Liver Program at Children's Healthcare of Atlanta

### Vincent Wong, MD

Professor, Head of Division of Gastroenterology and Hepatology at the Chinese University of Hong Kong and Director of Cheng Suen Man Shook Centre for Hepatitis Research

### Zobair Younossi, MD, MPH

Chairman and Professor of Medicine at Inova Fairfax Medical Campus

For more information about the NASH Roundtable, contact [nashroundtable@prosciento.com](mailto:nashroundtable@prosciento.com) or visit [www.nashroundtable.com](http://www.nashroundtable.com)

prosciento®  
ADVISE • ADVANCE • ACHIEVE

November 2021